市場調查報告書

全球重度躁動·攻擊性治療市場:成長,趨勢,及預測

Acute Agitation and Aggression Treatment Market - Growth, Trends, and Forecast (2020 - 2025)

出版商 Mordor Intelligence LLP 商品編碼 921934
出版日期 內容資訊 英文 111 Pages
商品交期: 2-3個工作天內
價格
全球重度躁動·攻擊性治療市場:成長,趨勢,及預測 Acute Agitation and Aggression Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
出版日期: 2020年01月01日內容資訊: 英文 111 Pages
簡介

本報告提供全球全球重度躁動·攻擊性治療市場的相關調查,提供市場機會和趨勢,成長及阻礙因素,各給藥途徑·藥物類別·終端用戶·地區的市場分析,競爭情形,主要企業的簡介等資訊。

目錄

第1章 簡介

  • 調查成果
  • 調查的前提條件
  • 調查範圍

第2章 調查方法

第3章 摘要整理

第4章 市場動態

  • 市場概況
  • 市場成長要素
    • 老年人口的增加和躁動患者的增加
    • 提高對躁動·攻擊性相關的意識
    • 開發躁動症狀的新治療方法的相關進行中的研究
  • 市場阻礙因素
    • 首選非藥物干預
    • 伴隨精神疾病的社會污名
  • 波特的五力分析

第5章 市場區隔

  • 各給藥途徑
    • 口服
    • 肌肉內
    • 其他
  • 各藥物類別
    • 抗精神病藥
    • 苯重氮基鹽
    • 其他
  • 各終端用戶
    • 醫院·門診病人手術中心
    • 精神科醫療設施
    • 其他
  • 各地區
    • 北美
    • 歐洲
    • 亞太地區
    • 中東·非洲
    • 南美

第6章 競爭情形

  • 企業簡介
    • Eli Lilly and Company
    • Pfizer, Inc.
    • Otsuka Holdings
    • GlaxoSmithKline
    • H. Lundbeck A/S
    • Johnson & Johnson
    • Bristol-Myers Squibb

第7章 市場機會及今後趨勢

目錄
Product Code: 67254

Market Overview

Global Acute Agitation and Aggression Treatment market are expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include a rise in the burden of mental illness and an increase in agitation in patients, an increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau's Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of the elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017 to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.

Scope of the Report

Agitation is generally defined as excessive verbal and/or motor behavior. It can escalate to aggression, which can be either verbal (vicious cursing and threats) or physical (toward objects or people). The scope of the market studied includes the drugs which acutely agitated patients are offered.

Key Market Trends

Anti-psychotics are Expected to Hold Significant Market Share in the Drug Class Segment

The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting.

North America Dominates the Market and Expected to do Same in the Forecast Period

As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer's Association, 2018). All these factors are expected to drive market growth in the region.

Competitive Landscape

The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rise in geriatric population and increase in agitation in patients
    • 4.2.2 Increase in focus on creating awareness about agitation and aggression
    • 4.2.3 Ongoing research on the development of novel treatment for agitation
  • 4.3 Market Restraints
    • 4.3.1 Preference for non-pharmacological interventions
    • 4.3.2 Social stigma associated with mental illness
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Route of Administration
    • 5.1.1 Oral
    • 5.1.2 Intramuscular
    • 5.1.3 Others
  • 5.2 By Drug Class
    • 5.2.1 Anti-psychotics
    • 5.2.2 Benzodiazepines
    • 5.2.3 Others
  • 5.3 By End Users
    • 5.3.1 Hospitals & Ambulatory Surgical Centers
    • 5.3.2 Psychiatric Care Facilities
    • 5.3.3 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Eli Lilly and Company
    • 6.1.2 Pfizer, Inc.
    • 6.1.3 Otsuka Holdings
    • 6.1.4 GlaxoSmithKline
    • 6.1.5 H. Lundbeck A/S
    • 6.1.6 Johnson & Johnson
    • 6.1.7 Bristol-Myers Squibb

7 MARKET OPPORTUNITIES AND FUTURE TRENDS